A PHARMACOKINETIC AND PHARMACOGENETIC STUDY OF CHEMOTHERAPEUTIC
化疗药物的药代动力学和药物遗传学研究
基本信息
- 批准号:7717512
- 负责人:
- 金额:$ 0.1万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2007
- 资助国家:美国
- 起止时间:2007-12-01 至 2008-05-31
- 项目状态:已结题
- 来源:
- 关键词:Anthracycline AntibioticsAnthracyclinesClassClinicalComputer Retrieval of Information on Scientific Projects DatabaseCytochrome P450 3A4DoseDrug KineticsEnzymesExposure toFundingGerm cell tumorGlycoproteinsGrantInstitutionLymphomaMalignant NeoplasmsOutcomePatientsPharmaceutical PreparationsPharmacogeneticsResearchResearch PersonnelResourcesSolidSourceTaxane CompoundTherapeuticToxic effectUnited States National Institutes of HealthVinca Alkaloidsexperiencetaxane
项目摘要
This subproject is one of many research subprojects utilizing the
resources provided by a Center grant funded by NIH/NCRR. The subproject and
investigator (PI) may have received primary funding from another NIH source,
and thus could be represented in other CRISP entries. The institution listed is
for the Center, which is not necessarily the institution for the investigator.
The vinca alkaloids, anthracyclines, taxanes and podophylotoxins are important classes of chemotherapeutic drugs in both hematological and solid malignancies. Despite this, there is relatively little information available regarding the disposition and optimal dosing of these agents. Prior pharmacokinetic studies have documented substantial inter-patient variability and clinical use is associated with unpredictable toxicities. It is desirable to optimize the dosing of these classes of agents especially as they are all used to treat curable malignancies including lymphomas and germ cell tumors. A pharmacogenetic study of enzymes that metabolize (cytochrome P450 3A4) and/or transport (p-glycoprotein) these agents paired with a pharmacokinetic analysis will provide a better understanding of the disposition of these agents. This increased understanding will help us better predict who gains an excess exposure to the drug and hence experience increased toxicity as well as those with potentially sub-therapeutic drug levels and potentially a poorer outcome from under-dosing.
这个子项目是众多研究子项目之一
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
CHRISTOPHER J SWEENEY其他文献
CHRISTOPHER J SWEENEY的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('CHRISTOPHER J SWEENEY', 18)}}的其他基金
Comprehensive genomic profiling of aggressive hormone sensitive prostate cancer
侵袭性激素敏感前列腺癌的全面基因组分析
- 批准号:
9886101 - 财政年份:2020
- 资助金额:
$ 0.1万 - 项目类别:
Comprehensive genomic profiling of aggressive hormone sensitive prostate cancer
侵袭性激素敏感前列腺癌的全面基因组分析
- 批准号:
10155449 - 财政年份:2020
- 资助金额:
$ 0.1万 - 项目类别:
Comprehensive genomic profiling of aggressive hormone sensitive prostate cancer
侵袭性激素敏感前列腺癌的全面基因组分析
- 批准号:
10453554 - 财政年份:2020
- 资助金额:
$ 0.1万 - 项目类别:
Cancer Detection & Diagnosis Research-2022-Comprehensive genomic profiling of aggressive hormone sensitive prostate cancer
癌症检测
- 批准号:
10890557 - 财政年份:2020
- 资助金额:
$ 0.1万 - 项目类别:
Evaluating a parthenolide analogue as a new bladder and kidney cancer therapy
评估小白菊内酯类似物作为一种新的膀胱癌和肾癌治疗方法
- 批准号:
8207261 - 财政年份:2010
- 资助金额:
$ 0.1万 - 项目类别:
Evaluating a parthenolide analogue as a new bladder and kidney cancer therapy
评估小白菊内酯类似物作为一种新的膀胱癌和肾癌治疗方法
- 批准号:
8028806 - 财政年份:2010
- 资助金额:
$ 0.1万 - 项目类别:
PHASE I, PHARMACOKINETIC, PHARMACODYNAMIC TRIAL OF PTK787 AND PACLITAXEL IN C
PTK787 和紫杉醇在 C 中的 I 期药代动力学、药效学试验
- 批准号:
7717530 - 财政年份:2007
- 资助金额:
$ 0.1万 - 项目类别:
A PHARMACOKINETIC AND PHARMACOGENETIC STUDY OF CHEMOTHERAPEUTIC
化疗药物的药代动力学和药物遗传学研究
- 批准号:
7606415 - 财政年份:2006
- 资助金额:
$ 0.1万 - 项目类别:
PHASE I, PHARMACOKINETIC, PHARMACODYNAMIC TRIAL OF PTK787 AND PACLITAXEL IN C
PTK787 和紫杉醇在 C 中的 I 期药代动力学、药效学试验
- 批准号:
7606433 - 财政年份:2006
- 资助金额:
$ 0.1万 - 项目类别:
A PHASE 1 SAFETY AND PHARMACOKINETIC STUDY OF SU011248 AND CAPECITABINE IN PA
SU011248 和卡培他滨在 PA 中的 1 期安全性和药代动力学研究
- 批准号:
7379149 - 财政年份:2005
- 资助金额:
$ 0.1万 - 项目类别:
相似海外基金
RUI: BIOPOLYMER - BIObricks POLYketide Metabolic EngineeRing platform for unraveling the biosynthesis of higher anthracyclines
RUI:BIOPOLYMER - BIObricks 聚酮化合物代谢工程平台,用于揭示高级蒽环类药物的生物合成
- 批准号:
2321976 - 财政年份:2024
- 资助金额:
$ 0.1万 - 项目类别:
Standard Grant
Mitigating Long-term Cardiotoxicity with Nanoparticle Encapsulated Anthracyclines
用纳米颗粒封装的蒽环类药物减轻长期心脏毒性
- 批准号:
10378678 - 财政年份:2021
- 资助金额:
$ 0.1万 - 项目类别:
Mitigating Long-term Cardiotoxicity with Nanoparticle Encapsulated Anthracyclines
用纳米颗粒封装的蒽环类药物减轻长期心脏毒性
- 批准号:
10195941 - 财政年份:2021
- 资助金额:
$ 0.1万 - 项目类别:
Validation and Implementation of Polygenic-Risk Prediction Models for Anthracyclines and Cisplatin in Pediatric Oncology
儿科肿瘤学中蒽环类药物和顺铂多基因风险预测模型的验证和实施
- 批准号:
429174 - 财政年份:2019
- 资助金额:
$ 0.1万 - 项目类别:
Studentship Programs
STOP-CA: Statins to prevent Cardiotoxicity from Anthracyclines
STOP-CA:他汀类药物可预防蒽环类药物的心脏毒性
- 批准号:
9351286 - 财政年份:2016
- 资助金额:
$ 0.1万 - 项目类别:
STOP-CA: Statins to prevent Cardiotoxicity from Anthracyclines
STOP-CA:他汀类药物可预防蒽环类药物的心脏毒性
- 批准号:
9176736 - 财政年份:2016
- 资助金额:
$ 0.1万 - 项目类别:
Linking defects in the uptake transporter OCT1 with cancer patients resistance towards anthracyclines
将摄取转运蛋白 OCT1 的缺陷与癌症患者对蒽环类药物的耐药性联系起来
- 批准号:
357190 - 财政年份:2016
- 资助金额:
$ 0.1万 - 项目类别:
Operating Grants
Anthracyclines disrupt Ca2+ signalling in cardiomyocytes: a contribution to cardiac toxicity
蒽环类药物破坏心肌细胞中的 Ca2 信号传导:导致心脏毒性
- 批准号:
nhmrc : 1021342 - 财政年份:2012
- 资助金额:
$ 0.1万 - 项目类别:
Project Grants
Examination of the Molecular Pharmacology of Anthracyclines Induced via their Interaction with Iron
通过与铁相互作用诱导的蒽环类药物的分子药理学研究
- 批准号:
nhmrc : 457310 - 财政年份:2007
- 资助金额:
$ 0.1万 - 项目类别:
NHMRC Project Grants